T. Rowe Price Associates
VKTX icon

T. Rowe Price Associates’s Viking Therapeutics VKTX Stock Holding History

T. Rowe Price Associates’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Buy
121,797
+16,310
+15% +$527K ﹤0.01% 1596
2026
Q1 		$3.43M Buy
105,487
+14,264
+16% +$458K ﹤0.01% 1588
2025
Q4 		$3.21M Buy
91,223
+5,732
+7% +$203K ﹤0.01% 1558
2025
Q3 		$2.25M Buy
85,491
+7,312
+9% +$218K ﹤0.01% 1681
2025
Q2 		$2.07M Buy
78,179
+8,090
+12% +$213K ﹤0.01% 1619
2025
Q1 		$1.69M Buy
70,089
+9,365
+15% +$296K ﹤0.01% 1688
2024
Q4 		$2.44M Sell
60,724
-1,945
-3% -$111K ﹤0.01% 1563
2024
Q3 		$3.97M Buy
62,669
+2,999
+5% +$176K ﹤0.01% 1371
2024
Q2 		$3.16M Sell
59,670
-1,747
-3% -$115K ﹤0.01% 1384
2024
Q1 		$5.04M Buy
61,417
+6,181
+11% +$275K ﹤0.01% 1217
2023
Q4 		$1.03M Buy
55,236
+13,784
+33% +$180K ﹤0.01% 1857
2023
Q3 		$459K Sell
41,452
-4,112
-9% -$58.8K ﹤0.01% 2149
2023
Q2 		$739K Buy
+45,564
New +$955K ﹤0.01% 1953

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

T. Rowe Price Associates's VKTX Position: Q2 2026 in Review

T. Rowe Price Associates increased its Viking Therapeutics (VKTX) stake by 15% in Q2 2026, buying an estimated $527K and bringing the position to 121,797 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1596.

T. Rowe Price Associates first reported a position in VKTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $5.04M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • T. Rowe Price Associates held 121,797 shares of Viking Therapeutics worth $4.75M as of Q2 2026.
  • T. Rowe Price Associates bought 16,310 Viking Therapeutics shares in Q2 2026, an estimated $527K.
  • Viking Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1596 holding.
  • T. Rowe Price Associates first reported a position in Viking Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Viking Therapeutics position peaked at $5.04M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.